← Leaderboards
Srinivasan Yegnasubramanian
Johns Hopkins University
$11,365,706
Attributed
$14,312,218
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,395,192 · 11
By mechanism
U54$7,229,447 · 4
P30$6,391,982 · 3
R01$4,778,280 · 2
P50$1,995,483 · 2
Top collaborators
- Angelo Michael De Marzo6 shared
- Sarah J Wheelan5 shared
- Franco Rafael D'Alessio4 shared
- Rachel L Damico4 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Brock A. Wester$10,280,878
- Angelo Michael De Marzo$8,441,808
- Ya-Chi Ho$15,158,105
- Gail Geller$4,593,729
- Linda J Van Eldik$37,023,709
Others in their field
Top investigators on “Genomics”
- Eric S Lander · Whitehead Institute For Biomedical Res$790,826,794
- Richard A Gibbs · Baylor College Of Medicine$661,700,875
- Richard K. Wilson · Washington University$497,388,134
- Leonard Freedman · Leidos Biomedical Research, Inc.$405,398,682
- David Heimbrook · Leidos Biomedical Research, Inc.$333,649,126
- Stacey Gabriel · Massachusetts Institute Of Technology$331,896,891
Research focus
GenomicsMalignant NeoplasmsProgramsMolecularMalignant Neoplasm Of ProstateTechnologyLaboratoriesDesignReportingCostProstateSamplingDisease ProgressionGenomeEpigenetic ProcessMutationDna Sequence AlterationCancer CellCellsTissuesLesionBasic ScienceResearch PersonnelData Analyses
Grant awards (43)
Prostate inflammatory lesions as a proving ground for development of aggressive prostate cancer$1,516,118
U54 · FY2025 · CA
Targeting Estrogenic pathways in Tregs to promote ARDS resolution - 5R01HL163881$684,280
R01 · FY2025 · HL
Project 3: Induction of synthetic lethality with combined DNMT and PARP inhibition$384,648
P50 · FY2025 · CA · contact PI
Experimental and Computational Genomics$299,086
P30 · FY2025 · CA · contact PI
Microenvironmental drivers of indolent to aggressive prostate cancer switch mediated by combined MYC Activation and PTEN loss$249,053
U54 · FY2025 · CA · contact PI
Prostate inflammatory lesions as a proving ground for development of aggressive prostate cancer$1,440,117
U54 · FY2024 · CA
Targeting Estrogenic pathways in Tregs to promote ARDS resolution$787,156
R01 · FY2024 · HL
Experimental and Computational Genomics$667,339
P30 · FY2024 · CA · contact PI
Project 3: Induction of synthetic lethality with combined DNMT and PARP inhibition$362,734
P50 · FY2024 · CA · contact PI
Microenvironmental drivers of indolent to aggressive prostate cancer switch mediated by combined MYC Activation and PTEN loss$235,040
U54 · FY2024 · CA · contact PI
Prostate inflammatory lesions as a proving ground for development of aggressive prostate cancer$1,485,601
U54 · FY2023 · CA
Targeting Estrogenic pathways in Tregs to promote ARDS resolution$809,772
R01 · FY2023 · HL
Experimental and Computational Genomics$667,339
P30 · FY2023 · CA · contact PI
Microenvironmental drivers of indolent to aggressive prostate cancer switch mediated by combined MYC Activation and PTEN loss$244,809
U54 · FY2023 · CA · contact PI
Spatial and mechanistic assessment of the role of stromal fibroblasts in driving emergence of aggressive prostate and bladder cancer$82,234
U54 · FY2023 · CA
Admin-Core-001$82,234
U54 · FY2023 · CA
Prostate inflammatory lesions as a proving ground for development of aggressive prostate cancer$1,558,904
U54 · FY2022 · CA
Targeting Estrogenic pathways in Tregs to promote ARDS resolution$816,322
R01 · FY2022 · HL
Experimental and Computational Genomics$667,339
P30 · FY2022 · CA · contact PI
Microenvironmental drivers of indolent to aggressive prostate cancer switch mediated by combined MYC Activation and PTEN loss$335,337
U54 · FY2022 · CA · contact PI
Experimental and Computational Genomics$591,956
P30 · FY2021 · CA · contact PI
Experimental and Computational Genomics$591,956
P30 · FY2020 · CA · contact PI
Experimental and Computational Genomics$591,956
P30 · FY2019 · CA · contact PI
Experimental and Computational Genomics$591,806
P30 · FY2018 · CA · contact PI
Role of TOP2B in generating complex genomic rearrangements in human cancer$336,150
R01 · FY2018 · CA · contact PI
Experimental and Computational Genomics$6,865
P30 · FY2018 · CA · contact PI
Experimental and Computational Genomics$2,069
P30 · FY2018 · CA · contact PI
Experimental and Computational Genomics$591,053
P30 · FY2017 · CA · contact PI
Role of TOP2B in generating complex genomic rearrangements in human cancer$336,150
R01 · FY2017 · CA · contact PI
Role of TOP2B in generating complex genomic rearrangements in human cancer$336,150
R01 · FY2016 · CA · contact PI
NEXT GENERATION SEQUENCING$229,477
P30 · FY2016 · CA · contact PI
Role of TOP2B in generating complex genomic rearrangements in human cancer$336,150
R01 · FY2015 · CA · contact PI
NEXT GENERATION SEQUENCING$229,477
P30 · FY2015 · CA · contact PI
Role of TOP2B in generating complex genomic rearrangements in human cancer$336,150
R01 · FY2014 · CA · contact PI
NEXT GENERATION SEQUENCING$220,231
P30 · FY2014 · CA · contact PI
NEXT GENERATION SEQUENCING$214,556
P30 · FY2013 · CA · contact PI
Identification and Validation of DNA Methylation Biomarkers for High Grade and/or$138,045
P50 · FY2013 · CA · contact PI
NEXT GENERATION SEQUENCING$229,477
P30 · FY2012 · CA · contact PI
Identification and Validation of DNA Methylation Biomarkers for High Grade and/or$224,470
P50 · FY2012 · CA · contact PI
Identification and Validation of DNA Methylation Biomarkers for High Grade and/or$214,615
P50 · FY2011 · CA · contact PI
Identification and Validation of DNA Methylation Biomarkers for High Grade and/or$223,656
P50 · FY2010 · CA · contact PI
Identification and Validation of DNA Methylation Biomarkers for High Grade and/or$223,655
P50 · FY2009 · CA · contact PI
Identification and Validation of DNA Methylation Biomarkers for High Grade and/or$223,660
P50 · FY2008 · CA · contact PI